STOKE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.56 USD | +4.81% |
|
-0.86% | +119.77% |
| 29/04 | Stoke Therapeutics Appoints Thomas Leggett CFO | MT |
| 29/04 | Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024 | CI |
Chart calendar Stoke Therapeutics, Inc.
1785451d5fc8.C1BNFVivgBilbckL3iOFpJVGqNVDAHlPnvM1B0uStqk.ZBEfUB_ozkHkHJl-tFHN3d5-3OIkOEom0qxmMjHjhe45OT5CO8fISvUAug~44259f86db1653a4c6fc35ed7c6d3a73
Upcoming events on Stoke Therapeutics, Inc.
Past events on Stoke Therapeutics, Inc.
| 10/04/2024 07:45 pm | Needham Healthcare Conference |
| 26/03/2024 02:00 am | STK-001 Approval Call |
| 26/03/2024 01:31 am | Q4 2023 Earnings Release |
| 11/01/2024 05:15 am | JPMorgan Healthcare Conference |
| 04/12/2023 10:30 pm | American Epilepsy Society Meeting - Poster No:3.110 |
| 02/12/2023 10:30 pm | American Epilepsy Society Meeting - Poster No:1.276 |
| 02/12/2023 10:30 pm | American Epilepsy Society Meeting - Poster No:1.279 |
| 02/12/2023 10:30 pm | American Epilepsy Society Meeting - Poster No: 1.233 |
| 07/11/2023 05:30 pm | Q3 2023 Earnings Release |
| 24/10/2023 06:30 pm | Extraordinary Shareholders Meeting |
| 26/09/2023 07:25 pm | Cantor Global Healthcare Conference |
| 10/08/2023 02:00 am | Canaccord Genuity Growth Conference |
| 07/08/2023 04:30 pm | Q2 2023 Earnings Release |
| 25/07/2023 05:30 pm | Monarch and Admiral and the Swallowtail Open-Label Extension Phase 1/2a Study Results Call |
| 13/06/2023 06:30 pm | Annual General Meeting |
| 11/05/2023 08:30 pm | Bank of America Healthcare Conference |
| 04/05/2023 04:30 pm | Q1 2023 Earnings Release |
| 15/03/2023 10:50 pm | Needham Neuroscience Forum |
| 06/03/2023 11:20 pm | Cowen Health Care Conference |
| 06/03/2023 05:30 pm | Q4 2022 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 12,4 11,7 5.96% | 8,78 9,52 -7.8% | 12,4 |
|
EBITDA Million USD | Released Forecast Spread | -35,2 -35,9 1.83% | -52,2 -51,6 -1.15% | -85,1 -82,6 -2.99% | -103 -99,4 -3.43% | -112 -104 -7.9% | -133 |
|
EBIT Million USD | Released Forecast Spread | -35,7 -35,8 0.28% | -53,0 -53,4 0.71% | -86,1 -85,4 -0.82% | -104 -106 1.49% | -115 -115 -0.1% | -129 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -32,3 -32,4 0.13% | -52,2 -52,1 -0.35% | -85,8 -84,7 -1.27% | -101 -103 2.25% | -105 -106 1.38% | -120 |
|
Net income Million USD | Released Forecast Spread | -32,3 -32,4 0.23% | -52,2 -52,1 -0.36% | -85,8 -84,9 -1.09% | -101 -104 2.36% | -105 -106 0.88% | -116 |
|
EPS USD | Released Forecast Spread | -1,80 -1,91 5.8% | -1,56 -1,56 -0.17% | -2,34 -2,30 -1.78% | -2,60 -2,65 2.01% | -2,38 -2,40 0.68% | -2,31 |
| Announcement Date | 23/03/20 | 09/03/21 | 10/03/22 | 06/03/23 | 25/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 3,00 37,5 -92% | 3,23 3,02 7.06% | 2,91 2,72 6.71% | 3,27 2,86 14.19% | 5,15 3,00 71.73% | -2,48 3,88 -164.03% | 3,31 3,19 3.78% | 2,80 3,22 -13.04% | 3,21 | 3,36 | 3,43 | 3,43 |
|
EBITDA Million USD | Released Forecast Spread | -24,3 -23,3 -4.33% | -24,5 | -24,9 -24,3 -2.75% | -26,8 -21,6 -23.78% | -26,6 -24,5 -8.25% | -24,1 -23,8 -1.44% | -32,7 -23,9 -36.63% | -24,5 | -29,0 -27,4 -5.61% | -31,5 | -33,0 | -34,3 | -34,8 |
|
EBIT Million USD | Released Forecast Spread | -24,5 -23,7 -3.62% | -24,8 12,6 -296.93% | -25,2 -19,4 -29.85% | -27,1 -27,1 -0.13% | -27,2 -28,8 5.77% | -24,7 -29,8 17.15% | -33,3 -28,2 -17.82% | -27,2 -28,9 5.72% | -29,6 -29,5 -0.2% | -31,3 | -31,9 | -33,1 | -33,8 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -24,4 -23,1 -5.9% | -24,6 9,37 -362.94% | -24,7 -25,5 3.34% | -26,1 -26,9 3.1% | -25,7 -28,0 8.42% | -22,5 -28,2 20.06% | -30,7 -27,5 -11.51% | -24,5 -28,3 13.22% | -27,0 -28,5 5.29% | -28,2 | -28,7 | -29,9 | -31,1 |
|
Net income Million USD | Released Forecast Spread | -24,4 -23,3 -4.92% | -24,6 12,7 -293.68% | -24,7 -25,8 4.35% | -26,1 -26,8 2.72% | -25,7 -28,1 8.85% | -22,5 -28,8 21.62% | -30,7 -27,9 -9.73% | -24,5 -28,2 12.88% | -27,0 -27,9 3.49% | -27,6 | -27,9 | -29,3 | -30,9 |
|
EPS USD | Released Forecast Spread | -0,66 -0,62 -5.97% | -0,66 0,32 -304.07% | -0,63 -0,68 6.96% | -0,66 -0,68 2.25% | -0,65 -0,70 7.38% | -0,53 -0,68 21.68% | -0,69 -0,63 -8.83% | -0,55 -0,63 13.04% | -0,60 -0,62 3.04% | -0,61 | -0,54 | -0,56 | -0,59 |
| Announcement Date | 10/03/22 | 10/05/22 | 08/08/22 | 14/11/22 | 06/03/23 | 04/05/23 | 07/08/23 | 07/11/23 | 25/03/24 | - | - | - | - |
| Today 04:00 pm | MODERNA, INC.: Q1 2024 Earnings Release |
| Today 04:30 pm | BLUEPRINT MEDICINES CORPORATION: Q1 2024 Earnings Release |
| Today 04:30 pm | KYMERA THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| Today 04:30 pm | IQVIA HOLDINGS INC.: Q1 2024 Earnings Release |
| Today 05:30 pm | ALNYLAM PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 06/05/2024 | REVOLUTION MEDICINES, INC.: Q1 2024 Earnings Release (Projected) |
| 06/05/2024 | SYNDAX PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
| 07/05/2024 | FORTREA HOLDINGS INC.: Q1 2024 Earnings Release |
| 07/05/2024 | VERVE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 07/05/2024 | OLEMA PHARMACEUTICALS, INC.: Q1 2024 Earnings Release (Projected) |
Past sector events for Stoke Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- STOK Stock
- Calendar Stoke Therapeutics, Inc.
